BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16952039)

  • 1. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
    Ueda S; Hironaka S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
    Gastric Cancer; 2006; 9(3):203-7. PubMed ID: 16952039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.
    Boku N; Ohtsu A; Shimada Y; Shirao K; Seki S; Saito H; Sakata Y; Hyodo I
    J Clin Oncol; 1999 Jan; 17(1):319-23. PubMed ID: 10458249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
    Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
    Sakamoto T; Yasui H; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Machida N; Todaka A; Tomita H; Tsushima T; Taniguchi H; Hamauchi S
    Int J Clin Oncol; 2010 Jun; 15(3):287-93. PubMed ID: 20217447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.
    Yoshida T; Yoshikawa T; Tsuburaya A; Kobayashi O; Hasegawa S; Osaragi T; Sairenji M
    Anticancer Res; 2006; 26(2B):1595-8. PubMed ID: 16619577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases.
    Yamao T; Ohta K; Ohyama S; Ishihara S; Chin K; Maruyama M; Takahashi T; Nakajima T
    Jpn J Clin Oncol; 2004 May; 34(5):255-61. PubMed ID: 15231860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice.
    Yoshida M; Boku N; Ohtsu A; Muto M; Nagashima F; Yoshida S
    Gastric Cancer; 2001; 4(3):144-9. PubMed ID: 11760080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer.
    Shen WC; Yang TS; Hsu HC; Chen JS
    Chang Gung Med J; 2011; 34(6):590-8. PubMed ID: 22196061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
    Nakashima K; Hironaka S; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Kojima T; Machida N
    Jpn J Clin Oncol; 2008 Dec; 38(12):810-5. PubMed ID: 18988666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.
    Baek JH; Kim JG; Sohn SK; Kim DH; Lee KB; Song HS; Kwon KY; Do YR; Ryoo HM; Bae SH; Park KU; Kim MK; Lee KH; Hyun MS; Chung HY; Yu W
    J Korean Med Sci; 2005 Dec; 20(6):966-70. PubMed ID: 16361806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians.
    Lim WT; Lim ST; Wong NS; Koo WH
    J Chemother; 2003 Aug; 15(4):400-5. PubMed ID: 12962370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
    Nagahori Y; Nagahori K; Hamaguchi Y; Fukushima T; Masui H; Mogaki M; Abe T
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1555-9. PubMed ID: 18799911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: a case report.
    Takahashi N; Suzuki H; Iwabuchi S; Yamazaki Y; Yanaga K
    Hepatogastroenterology; 2005; 52(61):326-8. PubMed ID: 15783061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
    Shimoyama S; Aoki F; Shimizu N; Tatsutomi Y; Mafune K; Kaminishi M
    Int J Clin Oncol; 2003 Feb; 8(1):49-52. PubMed ID: 12601543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer].
    Sugiyama T; Nishida T; Kataoka A; Imaishi K; Komai K; Ushijima K; Hasuo Y; Ookura N; Yakushiji M
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Sep; 48(9):827-34. PubMed ID: 8841050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
    Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
    Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
    Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
    Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical efficacy and safety of CPT-11+CDDP therapy as third-line chemotherapy for advanced and recurrent gastric cancer].
    Godai TI; Oshima T; Numata M; Fukahori M; Sato T; Makino H; Fujii S; Rino Y; Masuda M; Imada T; Kunisaki C
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):945-9. PubMed ID: 21677484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.